“Non-Preferred” Generics Increase Co-Pays for Triptans, Other Drugs
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The Migraine.com team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- Oster, G., & Fendrick, A.M. (2014). Is all “skin in the game” fair game? The problem with “non-preferred” generics. American Journal of Managed Care, 20(9), 693-695.
- Ornstein, C. “A new way insurers are shifting costs to the sick.” ProPublica website. Sept. 17, 2014. http://www.propublica.org/article/a-new-way-insurers-are-shifting-costs-to-the-sick
- Lantéri-Minet, M., Mick, G., & Allaf, B. (2012). Early dosing and efficacy of triptans in acute migraine treatment: the TEMPO study. Cephalalgia, 32(3), 226-235.